Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerRespiratory

PUBLISHER: Grand View Research | PRODUCT CODE: 1679416

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1679416

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Metastatic Lung Adenocarcinoma Treatment Market Growth & Trends:

The global metastatic lung adenocarcinoma treatment market size is estimated to reach USD 9.29 billion by 2030, expanding at a CAGR of 11.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

  • Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2024, the chemotherapy segment accounted for the largest revenue share of 36% in metastatic lung adenocarcinoma treatment market
  • The hospital segment accounts for the largest revenue share of 63.9% in 2024. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
  • The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors
  • The targeted therapy segment is anticipated to emerge as the fastest-growing segment and register a CAGR of 12.9% from 2025 to 2030, owing to its ability to target specific molecular drivers of cancer precisely.
Show more
Product Code: GVR-4-68040-431-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamic
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamic
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamic
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamic
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamic
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamic
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamic
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Spain Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Italy
      • 6.5.6.1. Key Country Dynamic
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Italy Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamic
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamic
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamic
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamic
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamic
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamic
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamic
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamic
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamic
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamic
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamic
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamic
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamic
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamic
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamic
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Eli Lilly and Company
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. AstraZeneca
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Bristol-Myers Squibb Company
      • 7.5.4.1. Participant's overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Boehringer Ingelheim International GmbH
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Novartis AG
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck KGaA (EMD Serono)
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. F. Hoffmann-La Roche Ltd
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. GSK plc.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. AbbVie Inc.
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-431-1

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 4. Global Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 5. Global Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 6. North America Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 7. North America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8. North America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9. U.S. Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10. U.S. Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 11. Canada Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12. Canada Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 13. Mexico Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 14. Mexico Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15. Europe Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 16. Europe Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17. Europe Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18. UK Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19. UK Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 20. Germany Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21. Germany Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 22. France Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23. France Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 24. Spain Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25. Spain Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 26. Italy Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27. Italy Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28. Denmark Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29. Denmark Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 30. Sweden Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31. Sweden Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 32. Norway Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 33. Norway Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37. China Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38. China Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 39. Japan Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40. Japan Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 41. India Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42. India Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43. South Korea Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44. South Korea Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 45. Australia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 46. Australia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 47. Thailand Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 48. Thailand Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 49. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 50. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52. Brazil Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53. Brazil Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 54. Argentina Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 55. Argentina Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59. South Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60. South Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 63. UAE Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 64. UAE Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 66. Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Metastatic Lung Adenocarcinoma Treatment Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Treatment and End Use Outlook (USD Million)
  • Fig. 10 Competitive Landscape
  • Fig. 11 Metastatic Lung Adenocarcinoma Treatment Market Dynamics
  • Fig. 12 Metastatic Lung Adenocarcinoma Treatment Market: Porter's Five Forces Analysis
  • Fig. 13 Metastatic Lung Adenocarcinoma Treatment Market: PESTLE Analysis
  • Fig. 14 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Segment Dashboard
  • Fig. 15 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Market Share Analysis, 2024 & 2030
  • Fig. 16 Chemotherapy Market, 2018 - 2030 (USD Million)
  • Fig. 17 Targeted Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy Market, 2018 - 2030 (USD Million)
  • Fig. 19 Radiation Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 20 Others Market, 2018 - 2030 (USD Million)
  • Fig. 21 Metastatic Lung Adenocarcinoma Treatment Market: End Use Segment Dashboard
  • Fig. 22 Metastatic Lung Adenocarcinoma Treatment Market: End Use Market Share Analysis, 2024 & 2030
  • Fig. 23 Hospitals Market, 2018 - 2030 (USD Million)
  • Fig. 24 Specialty Clinics Market, 2018 - 2030 (USD Million)
  • Fig. 25 Others Market, 2018 - 2030 (USD Million)
  • Fig. 26 Metastatic Lung Adenocarcinoma Treatment Market Revenue, By Region
  • Fig. 27 Regional Marketplace: Key Takeaways
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 North America Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Country Dynamics
  • Fig. 31 U.S. Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Country Dynamics
  • Fig. 33 Canada Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico Country Dynamics
  • Fig. 35 Mexico Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Country Dynamics
  • Fig. 38 UK Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Country Dynamics
  • Fig. 40 Germany Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 France Country Dynamics
  • Fig. 42 France Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Country Dynamics
  • Fig. 44 Spain Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy Country Dynamics
  • Fig. 46 Italy Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark Country Dynamics
  • Fig. 48 Denmark Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden Country Dynamics
  • Fig. 50 Sweden Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway Country Dynamics
  • Fig. 52 Norway Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 54 Japan Country Dynamics
  • Fig. 55 Japan Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 56 China Country Dynamics
  • Fig. 57 China Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 58 India Country Dynamics
  • Fig. 59 India Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea Country Dynamics
  • Fig. 61 South Korea Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia Country Dynamics
  • Fig. 63 Australia Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand Country Dynamics
  • Fig. 65 Thailand Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil Country Dynamics
  • Fig. 68 Brazil Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina Country Dynamics
  • Fig. 70 Argentina Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 71 Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa Country Dynamics
  • Fig. 73 South Africa Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia Country Dynamics
  • Fig. 75 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 76 UAE Country Dynamics
  • Fig. 77 UAE Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 78 Kuwait Key Country Dynamics
  • Fig. 79 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 80 Company Categorization
  • Fig. 81 Company Market Position Analysis
  • Fig. 82 Strategic Framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!